Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2015-04-30 | J. Martin Carroll has served as a director of our company since March 2015. ... The members of the Nominating and Corporate Governance Committee are Messrs. Thompson, Carroll, and LaPenta, Jr. Mr. Thompson serves as Chair. ... The Compensation Committee currently consists of Messrs. Collins, Carroll, and Thompson, with Mr. Collins serving as Chairman. Mr. Musing served on the Compensation Committee until June 23, 2014. |
| 2016-04-28 | J. Martin Carroll has served as a director of our company since March 2015. ... We believe Mr. Carroll's extensive experience as a pharmaceutical industry executive and his experience as a director of other publicly traded pharmaceutical companies provides the requisite qualifications, skills, perspectives, and experience that make him well qualified to serve on our Board of Directors. |
| 2017-04-25 | J. Martin Carroll has served as a director of our company since March 2015. ... Mr. Carroll received a B.A. in accounting and economics from the College of Holy Cross and a M.B.A. from Babson College. ... The following table and accompanying footnotes detail compensation paid to our directors for services rendered for the year ended December 31, 2016. J. Martin Carroll $74,250 fees earned or paid in cash, $89,503 option awards, total $163,753. |
| 2018-04-27 | J. Martin Carroll has served as a director of our company since March 2015. ... The Compensation Committee currently consists of Messrs. Collins, Thompson, and Carroll, with Mr. Collins serving as Chairman. ... J. Martin Carroll Fees Earned or Paid in Cash: $75,750, Option Awards: $165,115, Total: $240,865. |
| 2019-04-30 | J. Martin Carroll has served as a director of our company since March 2015. ... Member of Nominating and Corporate Governance Committee. Member of the Compensation Committee. ... Director Compensation table shows $80,750 fees earned in cash and $180,039 option awards, total $260,789. |
| 2020-05-04 | J. Martin Carroll has served as a director of our company since March 2015. ... Mr. Carroll received a B.A. in accounting and economics from the College of Holy Cross and a M.B.A. from Babson College. |
| 2021-04-14 | J. Martin Carroll has served as a director of our company since March 2015. Mr. Carroll previously served as President and Chief Executive Officer of Boehringer Ingelheim Corp. (U.S.) from 2003 until 2011. He also served as global head of strategy and development for Boehringer Ingelheim (Germany) from 2009 through 2012 and served as Chairman of the Board for a number of Boehringer Ingelheim companies. Previously, Mr. Carroll held positions of increasing responsibility with Merck & Co. Inc. from 1976 to 2001, including manufacturing, international (Japan) and marketing and sales. He left Merck serving as its Executive Vice President for Customer Marketing and Sales of the U.S. Human Health Division. From 1972 to 1976, Mr. Carroll served in the United States Air Force. Mr. Carroll has previously served on the board of directors for a number of organizations, including Accredo Health Group Inc., Vivus Inc. [NASDAQ: VVUS], Durata Therapeutics Inc. [NASDAQ: DRTX], and Gwynedd Mercy College, as well as PhRMA. He currently serves as a director of Mallinckrodt PLC [OTC: MNKKKQ] and Catalent, Inc. [NYSE: CTLT] and previously served as a director of Inotek Pharmaceuticals Corporation [NASDAQ: ITEK] from 2016 until its merger with Rocket Pharmaceuticals, Ltd. in 2018. |
Data sourced from SEC filings. Last updated: 2025-07-01